Asia · Regional markets · Korea Economic Daily

GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin

Published by Korea Economic Daily · South Korea 21 h ago

South Korea’s GC Biopharma Corp. and Hanmi Pharmaceutical Co. have licensed an experimental Fabry disease treatment to BioMarin Pharmaceutical Inc. in a ...

Read the full article on Korea Economic Daily Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.kedglobal.com)

Also worth reading

Tech in Asia

GC Biopharma, Hanmi strike Fabry drug deal worth up to $475 mn with BioMarin

Share

Also worth reading

Indonesia’s Blibli owner posts 46% revenue growth in Q3

US markets close lower as AI worries come to haunt Wall Street again

France gets budget warning as Fitch turns negative on rating

Raw sugar gains nearly 10% in October; robusta coffee 6% down

SC refers Krishna-Godavari basin gas dispute to mediation

Trump says US looking at whether Binance hack was by North Korea